01.12.2015 | Research article | Ausgabe 1/2015 Open Access

Lung function changes from childhood to adolescence: a seven-year follow-up study
- Zeitschrift:
- BMC Pulmonary Medicine > Ausgabe 1/2015
Competing interests
Authors’ contributions
Authors’ information
Background
Methods
Study population
Questionnaire
Spirometry
Statistical methods
Results
FEMALE
|
MALE
|
TOTAL
|
|||||||
---|---|---|---|---|---|---|---|---|---|
2003
|
2010
|
Δ/year
|
2003
|
2010
|
Δ/year
|
2003
|
2010
|
Δ/year
|
|
Mean
|
Mean
|
Mean
|
Mean
|
Mean
|
Mean
|
Mean
|
Mean
|
Mean
|
|
(sd)
|
(sd)
|
(sd)
|
(sd)
|
(sd)
|
(sd)
|
(sd)
|
(sd)
|
(sd)
|
|
AGE
|
4.5
|
11.7
|
7.34
|
4.5
|
11.8
|
7.23
|
4.5
|
11.8
|
7.30
|
(0.7)
|
(0.6)
|
(0.48)
|
(0.6)
|
(0.7)
|
(0.43)
|
(0.7)
|
(0.7)
|
(0.46)
|
|
HEIGHT (cm)
|
110.3
|
150.1
|
5.3
|
111.7
|
150.7
|
5.5
|
111.1
|
150.4
|
5.5
|
(6.2)
|
(8.5)
|
(0.7)
|
(6.3)
|
(8.8)
|
(0.7)
|
(6.3)
|
(8.7)
|
(0.7)
|
|
WEIGHT (Kg)
|
18.8
|
42.6
|
3.4
|
20.0
|
44.8
|
3.3
|
19.5
|
43.9
|
3.3
|
(3.2)
|
(9.3)
|
(1.2)
|
(3.8)
|
(11.3)
|
(1.0)
|
(3.6)
|
(10.5)
|
(1.0)
|
|
BMI%
|
15.4
|
18.6
|
0.41
|
15.9
|
19.0
|
0.44
|
15.7
|
18.8
|
0.43
|
(1.8)
|
(3.7)
|
(0.59)
|
(2.0)
|
(4.9)
|
(0.46)
|
(1.9)
|
(4.4)
|
(0.54)
|
|
FVC(ml)
|
1054
|
2647
|
221
|
1144
|
2842
|
231
|
1105
|
2756
|
227
|
(239)
|
(508)
|
(55)
|
(226)
|
(533)
|
(55)
|
(236)
|
(530)
|
(55)
|
|
FEV
1
(ml)
|
1048
|
2293
|
176
|
1127
|
2426
|
177
|
1093
|
2367
|
177
|
(224)
|
(420)
|
(44)
|
(211)
|
(460)
|
(52)
|
(220)
|
(447)
|
(48)
|
|
FEV1%/FVC
|
96.6
|
85.3
|
−1.7
|
96.3
|
83.7
|
−1.8
|
96.4
|
84.3
|
−1.8
|
(4.4)
|
(7.4)
|
(1.1)
|
(4.1)
|
(6.0)
|
(0.9)
|
(4.3)
|
(6.5)
|
(1.0)
|
|
FEF
25–75
(ml/s)
|
1561
|
2718
|
159
|
1735
|
2706
|
131
|
1660
|
2711
|
143
|
(385)
|
(728)
|
(88)
|
(949)
|
(731)
|
(162)
|
(761)
|
(729)
|
(136)
|
No symptoms
|
Early transient
|
Late onset
|
Persistent
|
|
---|---|---|---|---|
N
|
191
|
13
|
23
|
15
|
%
|
78.93
|
5.37
|
9.5
|
6.2
|
2003
|
2010
|
Δ/year
|
|||||
---|---|---|---|---|---|---|---|
Mean
|
p
|
Mean
|
p
|
p
|
|||
FEV
1
(ml)
|
Observed
|
1107.4
|
2435.9
|
180.4
|
|||
Predicted
|
1123.2
|
2497.5
|
188.3
|
||||
δ
|
−15.8
|
NS
|
−61.6
|
*
|
−7.9
|
*
|
|
95% CI of δ
|
(−32.8 - +5.6)
|
(−103.4 --19.8)
|
|||||
Z-score 50
tile
|
−0.138
|
−0.203
|
|||||
Z-score 5
tile
|
−1.583
|
−1.548
|
|||||
lln
|
879.5
|
2017.8
|
|||||
FVC (ml)
|
Observed
|
1120.7
|
2824.1
|
233.4
|
|||
Predicted
|
1216.0
|
2876.4
|
227.8
|
||||
δ
|
−95.2
|
**
|
−52.3
|
**
|
5.6
|
**
|
|
95% CI of δ
|
(−116.2 - -74.3)
|
(−91.9 - -12.7)
|
|||||
Z-score 50
tile
|
−0.645
|
−0.113
|
|||||
Z-score 5
tile
|
−1.954
|
−1.468
|
|||||
lln
|
943.9
|
2329.9
|
|||||
FEV
1
/FVC (%)
|
Observed
|
96.6
|
85.5
|
−1.57
|
|||
Predicted
|
92.9
|
87.1
|
−0.8
|
||||
δ
|
3.7
|
**
|
−2.4
|
**
|
−0.77
|
**
|
|
95% CI of δ
|
(+3.0 - +4.3)
|
(−2.4 - -0.8)
|
|||||
Z-score 50
tile
|
0.961
|
−0.207
|
|||||
Z-score 5
tile
|
−0.905
|
−1.664
|
|||||
lln
|
81.6
|
76.3
|
|||||
FEF
25–75
(ml/s)
|
Observed
|
1621.3
|
2766.9
|
152.8
|
|||
Predicted
|
1602.6
|
2955.8
|
185.2
|
||||
δ
|
18.7
|
NS
|
−269.6
|
**
|
−32.3
|
**
|
|
95% CI of δ
|
(−25.0 - +62.3)
|
(−269.6 - -108.2)
|
|||||
Z-score 50
tile
|
0.045
|
−0.306
|
|||||
Z-score 5
tile
|
−1.357
|
−1.912
|
|||||
lln
|
967.0
|
1954.3
|
2003
|
Δ/year
|
P<
|
||
---|---|---|---|---|
Mean
|
Mean
|
model
|
||
(C.I.)
|
(C.I.)
|
|||
FEV
1
(ml)
|
No symptoms
|
1108.8
|
181.9
|
NS
|
(1087.6-1129.9)
|
(176.0 -187.9)
|
|||
Early transient
|
1122.3
|
186.9
|
||
(1032.2-1212.4)
|
(161.8 - 212.1)
|
|||
Late onset
|
1105.7
|
171.5
|
||
(1045.31 -166.0)
|
(154.6 - 188.4)
|
|||
Persistent
|
1100.2
|
172.0
|
||
(1030.5 - 1169.9)
|
(152.4 - 191.5)
|
|||
FVC (ml)
|
No symptoms
|
1121.4
|
233.8 (228.4 - 239.3)
|
NS
|
(1100.6 - 1142.1)
|
||||
Early transient
|
1159.3
|
232.2
|
||
(1072.7-1245.8)
|
(208.4 - 255.9)
|
|||
Late onset
|
1134.6
|
229.0
|
||
(1072.3 - 1197.0)
|
(212.5 - 245.4)
|
|||
Persistent
|
1151.5
|
234.9
|
||
(1074.3 - 1228.7)
|
(214.5 - 255.4)
|
|||
FEV
1
/FVC (%)
|
No symptoms
|
96.5
|
−1.5
|
*
|
(95.9 - 97.2)
|
(−1.7 - -1.4)
|
|||
Early transient
|
94.2
|
−1.1
|
||
(91.5 - 97.0)
|
(−1.7 - -0.6)
|
|||
Late onset
|
96.7
|
−1.8
|
||
(94.9 - 98.5)
|
(−2.2 - -1.4)
|
|||
Persistent
|
95.9
|
−2.0 *
|
||
(93.8 - 98.0)
|
(−2.4 - -1.6)
|
|||
FEF
25–75
(ml/s)
|
No symptoms
|
1621.9
|
157.4
|
***
|
(1580.6 - 1663.1)
|
(146.8 - 168.0)
|
|||
Early transient
|
1531.5
|
158.6
|
||
(1353.4 - 1709.6)
|
(113.0 - 204.1)
|
|||
Late onset
|
1570.3
|
135.5 *
|
||
(1447.4 - 1693.1)
|
(104.0 - 166.9)
|
|||
Persistent
|
1506.4
|
113.7 **
|
||
(1354.2 - 1658.6)
|
(74.7 - 152.7)
|